CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Carbonic anhydrase staining levelsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06309459
NCT06309459N/ACompleted
CompareCT.gov

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy

Kahramanmaras Sutcu Imam University·observational·Posted Mar 13, 2024·Updated Mar 13, 2024

In Brief

An observational study evaluating Carbonic anhydrase staining levels for Triple Negative Breast Cancer and Carbonic Anhydrase IX. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsTriple Negative Breast Cancer, Carbonic Anhydrase IX
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 13, 2024
Enrollment StartAug 1, 2018
Primary CompletionMay 1, 2023
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 2.3 years ago

Interventions

Carbonic anhydrase staining levelsother

CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).